Who owns Maze Therapeutics, Inc. (MAZE)? Elite investor 13F holders
2 tracked elite investors reported holding Maze Therapeutics, Inc as of 2026-06-30, including Alphabet, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Alphabet | MAZE THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-07 00:00:00 | 41435317.00 USD | 1388583.000000 | Shares | hold | Original filing |
| Caligan Partners | MAZE THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| D.E. Shaw | MAZE THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 358647.00 USD | 12019.000000 | Shares | reduce | Original filing |
| Renaissance Technologies LLC | MAZE THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.